modelS01XA11
Extends from Pharmacokinetic.Models.PK_1C.
Information
| name: | Nandrolone | |
| ATC code: | S01XA11 | route: | intramuscular |
| compartments: | 1 | |
| dosage: | 100 | mg |
| volume of distribution: | 4.3 | L |
| clearance: | 1.6 | L/hr |
| other parameters in model implementation | ||
Nandrolone is a synthetic anabolic-androgenic steroid that is used medically for the treatment of anemia, osteoporosis, and other conditions requiring protein building and bone strengthening. Its use in sports is prohibited due to its performance-enhancing effects. The ATC code S01XA11 corresponds to ophthalmological use, but there is no evidence of nandrolone being used for this indication in approved clinical practice today.
Pharmacokinetics
Estimated typical pharmacokinetics for healthy adult males; no published PK studies for ophthalmic (S01XA11) route found, hence estimates based on systemic (intramuscular) nandrolone pharmacokinetics.
References
Kintz, P, et al., & Ludes, B (1999). [Norandrostenolone and noretiocholanolone: metabolite markers]. Acta clinica Belgica 53 Suppl 1 68–73. PUBMED:https://pubmed.ncbi.nlm.nih.gov/10216987
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)